Prostate Cancer Patient Case Study: How To Use ZOMETA®

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Prostate Cancer

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETAŽ Prostate Cancer Patient Case Study Dieter

Dieter V.

Aged 61 years
Manages a department store
Coaches his grandson's football team

Page

1 2 3 4 5

In patients like Dieter, the vicious cycle of bone destruction is ongoing

Osteoclasts and osteoblasts continually weaken bone in a vicious cycle of destruction^7,8

ZOMETA®: Osteoclasts and osteoblasts continually weaken bone in SREs

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA^® must be dosed every 3 to 4 weeks^7,9

Page

1 2 3 4 5

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

In patients like Dieter, the vicious cycle of bone destruction is ongoing

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA® must be dosed every 3 to 4 weeks7,9

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA^® must be dosed every 3 to 4 weeks^7,9